T-cell receptor signaling in peripheral T-cell lymphoma - A review of patterns of alterations in a central growth regulatory pathway

Current Hematologic Malignancy Reports

Volumn 8, Issue 3, 2013, Pages 163-172

  Warner, Kathrin ^a   Weit, Nicole ^a   Crispatzu, Giuliano ^a   Admirand, Joan ^b   Jones, Dan ^c   Herling, Marco ^a,d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Clinical Pathology Associates   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Anaplastic large cell lymphoma (ALCL); Mature T cell lymphoma leukemia; Peripheral T cell lymphoma (PTCL); T cell homeostasis; T cell prolymphocytic leukemia (T PLL); T cell receptor (TCR)

Indexed keywords

ANTIGEN; AUTOANTIGEN; DASATINIB; ENZASTAURIN; FOSTAMATINIB; HLA ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE C BETA; PROTEIN KINASE SYK; RAPAMYCIN DERIVATIVE; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL MATURATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; GROWTH REGULATION; HLA SYSTEM; HUMAN; IMMUNOSTIMULATION; INTRACELLULAR SIGNALING; LYMPHOCYTE FUNCTION; NONHUMAN; PATHOGENESIS; PERIPHERAL T CELL LYMPHOMA; T LYMPHOCYTE; TUMOR GROWTH; CELL TRANSFORMATION; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION;

EID: 84883850790     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-013-0165-2     Document Type: Article

References (55)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: IARC; 2008.
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-30.
3. • Pileri SA, Piccaluga PP. New molecular insights into peripheral T cell lymphomas. J Clin Invest. 2012;122(10):3448-55. This is an up-to-date review by experts from the European T-Cell Lymphoma Study Group on our current concepts of the molecular pathogenesis and histogenesis of major subsets of nodal peripheral T-cell lymphomas.
4. Smith-Garvin J, Koretzky G, Jordan M. T cell activation. Annu Rev Immunol. 2009;27:591-619.
5. Acuto O, Di Bartolo V, Michel F. Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat Rev Immunol. 2008;8(9):699-712.
6. Baker M, Gamble J, Tooze R, et al. Development of T-leukaemias in CD45 tyrosine phosphatase-deficient mutant lck mice. EMBO J. 2000;19(17):4644-54.
7. Nakayama T, Yamashita M. The TCR-mediated signaling pathways that control the direction of helper T cell differentiation. Semin Immunol. 2010;22(5):303-9.
8. Jones D, O'Hara C, Kraus MD, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood. 2000;96(2):685-90.
9. Zhou L, Chong MMW, Littman DR. Plasticity of CD4+ T cell lineage differentiation. Immunity. 2009;30(5):646-55.
10. Létourneau S, Krieg C, Pantaleo G, Boyman O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol. 2009;123(4):758-62.
11. Boyman O, Létourneau S, Krieg C, Sprent J. Homeostatic proliferation and survival of naïve and memory T cells. Eur J Immunol. 2009;39(8):2088-94.
12. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity. 2008;29(6):848-62.
13. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol. 2007;7(7):532-42.
14. An J, Fujiwara H, Suemori K, et al. Activation of T-cell receptor signaling in peripheral T-cell lymphoma cells plays an important role in the development of lymphoma-associated hemophagocytosis. Int J Hematol. 2011;93(2):176-85.
15. Crispín JC, Tsokos GC. Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmun Rev. 2009;8(3):190-5.
16. Burg G, Kempf W, Haeffner A, et al. From inflammation to neoplasia: new concepts in the pathogenesis of cutaneous lymphomas. Recent Results Cancer Res. 2002;160:271-80.
17. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol. 2004;4(3):211-22.
18. Morgan SM, Hodges E, Mitchell TJ, et al. Molecular analysis of T-cell receptor β genes in cutaneous T-cell lymphoma reveals Jβ1 bias. J Invest Dermatol. 2006;126(8):1893-9.
19. Hahtola S, Tuomela S, Elo L, et al. Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma. Clin Cancer Res. 2006;12(16):4812-21.
20. Dummer R, Geertsen R, Ludwig E, Niederer E, Burg G. Sézary syndrome, T-helper 2 cytokines and accessory factor-1 (AF-1). Leuk Lymphoma. 1998;28(5-6):515-22.
21. Papadavid E, Economidou J, Psarra A, et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2003;148(4):709-18.
22. Abdulla F, Duvic M, Kim Y. T-cell lymphomas. Totowa, NJ: Humana Press; 2013.
23. Martínez-Delgado B, Cuadros M, Honrado E, et al. Differential expression of NF-κB pathway genes among peripheral T-cell lymphomas. Leukemia. 2005;19(12):2254-63.
24. Wlodarski MW, O'Keefe C, Howe EC, et al. Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood. 2005;106(8):2769-80.
25. Garrido P, Ruiz-Cabello F, Bárcena P, et al. Monoclonal TCR-Vβ13.1+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. Blood. 2007;109(11):4890-8.
26. Lima M, Almeida J, Santos AH, et al. Immunophenotypic analysis of the TCR-vβ repertoire in 98 persistent expansions of CD3+/TCR-αβ + large granular lymphocytes. Am J Pathol. 2001;159(5):1861-8.
27. Sandberg Y, Almeida J, Gonzalez M, et al. TCRγ/δ + large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCRγ/δ + T-cells. Leukemia. 2006;20(3):505-13.
28. O'Keefe CL, Plasilova M, Wlodarski M, et al. Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. J Immunol. 2004;172(3):1960-9.
29. Sandberg Y. Basic and clinical aspects of the T-cell receptor in mature T-cell malignancies. Ph.D. Thesis. Erasmus University Rotterdam; 2007. p. 221.
30. •• Clemente MJ, Wlodarski MW, Makishima H, et al. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood. 2011;118(16):4384-93. This paper instructively shows for T-LGL what many researchers in the field of mature T-cell lymphomas have been observing, namely a marked clonal dynamics of retraction and expansion of various TCR-defined clones within one tumor. It also contributes particularly to our understanding of T-LGL representing a spectrum of gradual overlap between reactive lesions and overt malignant neoplasms.
31. Davey MP, Starkebaum G, Loughran TP. CD3+ leukemic large granular lymphocytes utilize diverse T-cell receptor Vβ genes. Blood. 1995;85(1):146-50.
32. Loughran TP, Hadlock KG, Perzova R, et al. Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia. Br J Haematol. 1998;101(2):318-24.
33. Yawalkar N, Ferenczi K, Jones DA, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood. 2003;102(12):4059- 66.
34. Jackow CM, Cather JC, Hearne V, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor Vβ gene expansion. Blood. 1997;89(1):32-40.
35. Abrams JT, Balin BJ, Vonderheid EC. Association between Sézary T cell-activating factor, Chlamydia pneumoniae, and cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001;941:69-85.
36. Tissier F, Martinon F, Camilleri-Broët S, et al. T-cell receptor Vβ repertoire in nodal non-anaplastic peripheral T-cell lymphomas. Pathol Res Pract. 2002;198(6):389-95.
37. Hodges E, Edwards SE, Howell WM, Smith JL. Polymerase chain reaction amplification analyses of clonality in T-cell malignancy including peripheral T-cell lymphoma. Leukemia. 1994;8(2):295-8.
38. Tembhare P, Yuan CM, Xi L, et al. Flow cytometric immunophenotypic assessment of T-cell clonality by Vβ repertoire analysis. Am J Clin Pathol. 2011;135(6):890-900.
39. •• Newrzela S, Al-Ghaili N, Heinrich T, et al. T-cell receptor diversity prevents T-cell lymphoma development. Leukemia. 2012;26(12):2499-507. Mature T cells have been considered to be largely resistant to (experimental) transformation by most known T-cell oncogenes. However, these researchers present data that indicate that in a background of clonal T-cell restriction, as for example observed during senescence or in lymphopenia, the outgrowth of mature T-cell lymphomas is facilitated. This supports a model in which homeostatic mechanisms that stabilize the diversity of the normal T-cell repertoire, e.g. clonal competition, also control the emergence of potentially malignant T-cell clones.
40. + T-cell lymphomas. This distinguishes these tumors from other subsets, e.g. PTCL-nos, and supports the TCR-based concept of a functional categorization of mature T-cell tumors outlined here.
41. Admirand J, Herling M, Patel K, et al. T-cell receptor signaling and growth pathways in T-cell tumors. Mod Pathol. 2005;18:220A.
42. Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008;111(1):328-37.
43. Herling M, Khoury JD, Washington LT, et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood. 2004;104(2):328-35.
44. Hoyer KK, Herling M, Bagrintseva K, et al. T cell leukemia-1 modulates TCR signal strength and IFN-γ levels through phosphatidylinositol 3-kinase and protein kinase c pathway activation. J Immunol. 2005;175(2):864-73.
45. Herling M, Patel KA, Weit N, et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood. 2009;114(21):4675-86.
46. Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia. 2006;20(2):313-8.
47. Feldman AL, Sun DX, Law ME, et al. Overexpression of SYK tyrosine kinase in peripheral T-cell lymphomas. Leukemia. 2008;22(6):1139-43.
48. Travert M, Huang Y, De Leval L, et al. Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood. 2012;119(24):5795-806.
49. Ortiz S, Lee W, Smith D, et al. Comparative analyses of differentially induced T-cell receptor-mediated phosphorylation pathways in T lymphoma cells. Exp Biol Med (Maywood). 2010;235(12):1450-63.
50. • Pechloff K, Holch J, Ferch U, et al. The fusion kinase ITK-SYK mimics a T-cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T-cell lymphoma. J Exp Med. 2010;207(5):1031-44. In the context of the recurrence of the t(5;9)(q33;q22) in a subset of PTCL-nos and the frequently high levels of SYK across many mature T-cell tumors, these authors provide experimental evidence of the transforming capacity of the ITK-SYK fusion tyrosine kinase in peripheral T-cells. Their work supports our TCR-based model by showing that constitutive TCR signaling is a strong oncogenic force.
51. Dierks C, Adrian F, Fisch P, et al. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res. 2010;70(15):6193-204.
52. Amin HM, Lai R. Pathobiology of ALK + anaplastic large-cell lymphoma. Blood. 2007;110(7):2259-67.
53. Armitage JO. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(5):511-9.
54. Hiromura M, Okada F, Obata T, et al. Inhibition of AKT kinase activity by a peptide spanning the βA strand of the proto-oncogene TCL1. J Biol Chem. 2004;279(51):53407-18.
55. Berger CL, Longley J, Hanlon D, Girardi M, Edelson R. The clonotypic T-cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001;941:106-22.